The global market for Fabry Disease Therapeutic was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Fabry Disease Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fabry Disease Therapeutic.

The Fabry Disease Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Fabry Disease Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Fabry Disease Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Fabry Disease Therapeutic Market Report

Report Metric	Details
Report Name	Fabry Disease Therapeutic Market
CAGR	5%
Segment by Type	Enzyme Replacement Therapy Alternative therapies
Segment by Application	Hospitals Clinics Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amicus therapeutics, Takeda, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva pharmaceutical Industries Ltd., Merc & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., Green Cross Corp.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fabry Disease Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Fabry Disease Therapeutic Market report?

Ans: The main players in the Fabry Disease Therapeutic Market are Amicus therapeutics, Takeda, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva pharmaceutical Industries Ltd., Merc & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., Green Cross Corp.

What are the Application segmentation covered in the Fabry Disease Therapeutic Market report?

Ans: The Applications covered in the Fabry Disease Therapeutic Market report are Hospitals, Clinics, Other

What are the Type segmentation covered in the Fabry Disease Therapeutic Market report?

Ans: The Types covered in the Fabry Disease Therapeutic Market report are Enzyme Replacement Therapy, Alternative therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Fabry Disease Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Enzyme Replacement Therapy

1.2.3 Alternative therapies

1.3 Market by Application

1.3.1 Global Fabry Disease Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Fabry Disease Therapeutic Market Perspective (2020-2031)

2.2 Global Fabry Disease Therapeutic Growth Trends by Region

2.2.1 Global Fabry Disease Therapeutic Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Fabry Disease Therapeutic Historic Market Size by Region (2020-2025)

2.2.3 Fabry Disease Therapeutic Forecasted Market Size by Region (2026-2031)

2.3 Fabry Disease Therapeutic Market Dynamics

2.3.1 Fabry Disease Therapeutic Industry Trends

2.3.2 Fabry Disease Therapeutic Market Drivers

2.3.3 Fabry Disease Therapeutic Market Challenges

2.3.4 Fabry Disease Therapeutic Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Fabry Disease Therapeutic Players by Revenue

3.1.1 Global Top Fabry Disease Therapeutic Players by Revenue (2020-2025)

3.1.2 Global Fabry Disease Therapeutic Revenue Market Share by Players (2020-2025)

3.2 Global Fabry Disease Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Fabry Disease Therapeutic Revenue

3.4 Global Fabry Disease Therapeutic Market Concentration Ratio

3.4.1 Global Fabry Disease Therapeutic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Fabry Disease Therapeutic Revenue in 2024

3.5 Global Key Players of Fabry Disease Therapeutic Head office and Area Served

3.6 Global Key Players of Fabry Disease Therapeutic, Product and Application

3.7 Global Key Players of Fabry Disease Therapeutic, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Fabry Disease Therapeutic Breakdown Data by Type

4.1 Global Fabry Disease Therapeutic Historic Market Size by Type (2020-2025)

4.2 Global Fabry Disease Therapeutic Forecasted Market Size by Type (2026-2031)

5 Fabry Disease Therapeutic Breakdown Data by Application

5.1 Global Fabry Disease Therapeutic Historic Market Size by Application (2020-2025)

5.2 Global Fabry Disease Therapeutic Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Fabry Disease Therapeutic Market Size (2020-2031)

6.2 North America Fabry Disease Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Fabry Disease Therapeutic Market Size by Country (2020-2025)

6.4 North America Fabry Disease Therapeutic Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Fabry Disease Therapeutic Market Size (2020-2031)

7.2 Europe Fabry Disease Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Fabry Disease Therapeutic Market Size by Country (2020-2025)

7.4 Europe Fabry Disease Therapeutic Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Fabry Disease Therapeutic Market Size (2020-2031)

8.2 Asia-Pacific Fabry Disease Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2020-2025)

8.4 Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Fabry Disease Therapeutic Market Size (2020-2031)

9.2 Latin America Fabry Disease Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Fabry Disease Therapeutic Market Size by Country (2020-2025)

9.4 Latin America Fabry Disease Therapeutic Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Fabry Disease Therapeutic Market Size (2020-2031)

10.2 Middle East & Africa Fabry Disease Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2020-2025)

10.4 Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amicus therapeutics

11.1.1 Amicus therapeutics Company Details

11.1.2 Amicus therapeutics Business Overview

11.1.3 Amicus therapeutics Fabry Disease Therapeutic Introduction

11.1.4 Amicus therapeutics Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.1.5 Amicus therapeutics Recent Development

11.2 Takeda

11.2.1 Takeda Company Details

11.2.2 Takeda Business Overview

11.2.3 Takeda Fabry Disease Therapeutic Introduction

11.2.4 Takeda Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.2.5 Takeda Recent Development

11.3 Genzyme-Sanofi

11.3.1 Genzyme-Sanofi Company Details

11.3.2 Genzyme-Sanofi Business Overview

11.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Introduction

11.3.4 Genzyme-Sanofi Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.3.5 Genzyme-Sanofi Recent Development

11.4 Protalix

11.4.1 Protalix Company Details

11.4.2 Protalix Business Overview

11.4.3 Protalix Fabry Disease Therapeutic Introduction

11.4.4 Protalix Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.4.5 Protalix Recent Development

11.5 Sanofi-Aventis LLC

11.5.1 Sanofi-Aventis LLC Company Details

11.5.2 Sanofi-Aventis LLC Business Overview

11.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Introduction

11.5.4 Sanofi-Aventis LLC Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.5.5 Sanofi-Aventis LLC Recent Development

11.6 Novartis Pharmaceuticals

11.6.1 Novartis Pharmaceuticals Company Details

11.6.2 Novartis Pharmaceuticals Business Overview

11.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Introduction

11.6.4 Novartis Pharmaceuticals Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.6.5 Novartis Pharmaceuticals Recent Development

11.7 Pfizer

11.7.1 Pfizer Company Details

11.7.2 Pfizer Business Overview

11.7.3 Pfizer Fabry Disease Therapeutic Introduction

11.7.4 Pfizer Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.7.5 Pfizer Recent Development

11.8 Bristol-Myers Squibb Company

11.8.1 Bristol-Myers Squibb Company Company Details

11.8.2 Bristol-Myers Squibb Company Business Overview

11.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Introduction

11.8.4 Bristol-Myers Squibb Company Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.8.5 Bristol-Myers Squibb Company Recent Development

11.9 GlaxoSmithKline plc

11.9.1 GlaxoSmithKline plc Company Details

11.9.2 GlaxoSmithKline plc Business Overview

11.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Introduction

11.9.4 GlaxoSmithKline plc Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.9.5 GlaxoSmithKline plc Recent Development

11.10 Amgen Inc.

11.10.1 Amgen Inc. Company Details

11.10.2 Amgen Inc. Business Overview

11.10.3 Amgen Inc. Fabry Disease Therapeutic Introduction

11.10.4 Amgen Inc. Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.10.5 Amgen Inc. Recent Development

11.11 Teva pharmaceutical Industries Ltd.

11.11.1 Teva pharmaceutical Industries Ltd. Company Details

11.11.2 Teva pharmaceutical Industries Ltd. Business Overview

11.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Introduction

11.11.4 Teva pharmaceutical Industries Ltd. Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.11.5 Teva pharmaceutical Industries Ltd. Recent Development

11.12 Merc & Co.

11.12.1 Merc & Co. Company Details

11.12.2 Merc & Co. Business Overview

11.12.3 Merc & Co. Fabry Disease Therapeutic Introduction

11.12.4 Merc & Co. Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.12.5 Merc & Co. Recent Development

11.13 AbbVie Inc.

11.13.1 AbbVie Inc. Company Details

11.13.2 AbbVie Inc. Business Overview

11.13.3 AbbVie Inc. Fabry Disease Therapeutic Introduction

11.13.4 AbbVie Inc. Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.13.5 AbbVie Inc. Recent Development

11.14 Takeda Pharmaceutical Co. Ltd.

11.14.1 Takeda Pharmaceutical Co. Ltd. Company Details

11.14.2 Takeda Pharmaceutical Co. Ltd. Business Overview

11.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Introduction

11.14.4 Takeda Pharmaceutical Co. Ltd. Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.14.5 Takeda Pharmaceutical Co. Ltd. Recent Development

11.15 Green Cross Corp.

11.15.1 Green Cross Corp. Company Details

11.15.2 Green Cross Corp. Business Overview

11.15.3 Green Cross Corp. Fabry Disease Therapeutic Introduction

11.15.4 Green Cross Corp. Revenue in Fabry Disease Therapeutic Business (2020-2025)

11.15.5 Green Cross Corp. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novartis Pharmaceuticals

Pfizer Inc

Bristol Myers Squibb Company

GlaxoSmithKline PLC

Amgen Inc

Teva Pharmaceutical Industries Ltd

Merc & Co.

AbbVie

Takeda Pharmaceutical Co Ltd

Green Cross Corp

List of Tables

Table 1. Global Fabry Disease Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Enzyme Replacement Therapy

Table 3. Key Players of Alternative therapies

Table 4. Global Fabry Disease Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Fabry Disease Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Fabry Disease Therapeutic Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Fabry Disease Therapeutic Market Share by Region (2020-2025)

Table 8. Global Fabry Disease Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Fabry Disease Therapeutic Market Share by Region (2026-2031)

Table 10. Fabry Disease Therapeutic Market Trends

Table 11. Fabry Disease Therapeutic Market Drivers

Table 12. Fabry Disease Therapeutic Market Challenges

Table 13. Fabry Disease Therapeutic Market Restraints

Table 14. Global Fabry Disease Therapeutic Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Fabry Disease Therapeutic Market Share by Players (2020-2025)

Table 16. Global Top Fabry Disease Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2024)

Table 17. Ranking of Global Top Fabry Disease Therapeutic Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Fabry Disease Therapeutic Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Fabry Disease Therapeutic, Headquarters and Area Served

Table 20. Global Key Players of Fabry Disease Therapeutic, Product and Application

Table 21. Global Key Players of Fabry Disease Therapeutic, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Fabry Disease Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Fabry Disease Therapeutic Revenue Market Share by Type (2020-2025)

Table 25. Global Fabry Disease Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Fabry Disease Therapeutic Revenue Market Share by Type (2026-2031)

Table 27. Global Fabry Disease Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Fabry Disease Therapeutic Revenue Market Share by Application (2020-2025)

Table 29. Global Fabry Disease Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Fabry Disease Therapeutic Revenue Market Share by Application (2026-2031)

Table 31. North America Fabry Disease Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Fabry Disease Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Fabry Disease Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Fabry Disease Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Fabry Disease Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Fabry Disease Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Fabry Disease Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Fabry Disease Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Fabry Disease Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Fabry Disease Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Fabry Disease Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 46. Amicus therapeutics Company Details

Table 47. Amicus therapeutics Business Overview

Table 48. Amicus therapeutics Fabry Disease Therapeutic Product

Table 49. Amicus therapeutics Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 50. Amicus therapeutics Recent Development

Table 51. Takeda Company Details

Table 52. Takeda Business Overview

Table 53. Takeda Fabry Disease Therapeutic Product

Table 54. Takeda Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 55. Takeda Recent Development

Table 56. Genzyme-Sanofi Company Details

Table 57. Genzyme-Sanofi Business Overview

Table 58. Genzyme-Sanofi Fabry Disease Therapeutic Product

Table 59. Genzyme-Sanofi Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 60. Genzyme-Sanofi Recent Development

Table 61. Protalix Company Details

Table 62. Protalix Business Overview

Table 63. Protalix Fabry Disease Therapeutic Product

Table 64. Protalix Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 65. Protalix Recent Development

Table 66. Sanofi-Aventis LLC Company Details

Table 67. Sanofi-Aventis LLC Business Overview

Table 68. Sanofi-Aventis LLC Fabry Disease Therapeutic Product

Table 69. Sanofi-Aventis LLC Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 70. Sanofi-Aventis LLC Recent Development

Table 71. Novartis Pharmaceuticals Company Details

Table 72. Novartis Pharmaceuticals Business Overview

Table 73. Novartis Pharmaceuticals Fabry Disease Therapeutic Product

Table 74. Novartis Pharmaceuticals Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 75. Novartis Pharmaceuticals Recent Development

Table 76. Pfizer Company Details

Table 77. Pfizer Business Overview

Table 78. Pfizer Fabry Disease Therapeutic Product

Table 79. Pfizer Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 80. Pfizer Recent Development

Table 81. Bristol-Myers Squibb Company Company Details

Table 82. Bristol-Myers Squibb Company Business Overview

Table 83. Bristol-Myers Squibb Company Fabry Disease Therapeutic Product

Table 84. Bristol-Myers Squibb Company Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 85. Bristol-Myers Squibb Company Recent Development

Table 86. GlaxoSmithKline plc Company Details

Table 87. GlaxoSmithKline plc Business Overview

Table 88. GlaxoSmithKline plc Fabry Disease Therapeutic Product

Table 89. GlaxoSmithKline plc Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 90. GlaxoSmithKline plc Recent Development

Table 91. Amgen Inc. Company Details

Table 92. Amgen Inc. Business Overview

Table 93. Amgen Inc. Fabry Disease Therapeutic Product

Table 94. Amgen Inc. Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 95. Amgen Inc. Recent Development

Table 96. Teva pharmaceutical Industries Ltd. Company Details

Table 97. Teva pharmaceutical Industries Ltd. Business Overview

Table 98. Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Product

Table 99. Teva pharmaceutical Industries Ltd. Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 100. Teva pharmaceutical Industries Ltd. Recent Development

Table 101. Merc & Co. Company Details

Table 102. Merc & Co. Business Overview

Table 103. Merc & Co. Fabry Disease Therapeutic Product

Table 104. Merc & Co. Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 105. Merc & Co. Recent Development

Table 106. AbbVie Inc. Company Details

Table 107. AbbVie Inc. Business Overview

Table 108. AbbVie Inc. Fabry Disease Therapeutic Product

Table 109. AbbVie Inc. Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 110. AbbVie Inc. Recent Development

Table 111. Takeda Pharmaceutical Co. Ltd. Company Details

Table 112. Takeda Pharmaceutical Co. Ltd. Business Overview

Table 113. Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Product

Table 114. Takeda Pharmaceutical Co. Ltd. Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 115. Takeda Pharmaceutical Co. Ltd. Recent Development

Table 116. Green Cross Corp. Company Details

Table 117. Green Cross Corp. Business Overview

Table 118. Green Cross Corp. Fabry Disease Therapeutic Product

Table 119. Green Cross Corp. Revenue in Fabry Disease Therapeutic Business (2020-2025) & (US$ Million)

Table 120. Green Cross Corp. Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Fabry Disease Therapeutic Picture

Figure 2. Global Fabry Disease Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Fabry Disease Therapeutic Market Share by Type: 2024 VS 2031

Figure 4. Enzyme Replacement Therapy Features

Figure 5. Alternative therapies Features

Figure 6. Global Fabry Disease Therapeutic Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Fabry Disease Therapeutic Market Share by Application: 2024 VS 2031

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Other Case Studies

Figure 11. Fabry Disease Therapeutic Report Years Considered

Figure 12. Global Fabry Disease Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Fabry Disease Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Fabry Disease Therapeutic Market Share by Region: 2024 VS 2031

Figure 15. Global Fabry Disease Therapeutic Market Share by Players in 2024

Figure 16. Global Top Fabry Disease Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Fabry Disease Therapeutic Revenue in 2024

Figure 18. North America Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Fabry Disease Therapeutic Market Share by Country (2020-2031)

Figure 20. United States Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Fabry Disease Therapeutic Market Share by Country (2020-2031)

Figure 24. Germany Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Fabry Disease Therapeutic Market Share by Region (2020-2031)

Figure 32. China Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Fabry Disease Therapeutic Market Share by Country (2020-2031)

Figure 40. Mexico Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Fabry Disease Therapeutic Market Share by Country (2020-2031)

Figure 44. Turkey Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Fabry Disease Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Amicus therapeutics Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 48. Takeda Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 49. Genzyme-Sanofi Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 50. Protalix Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 51. Sanofi-Aventis LLC Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 52. Novartis Pharmaceuticals Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 53. Pfizer Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 54. Bristol-Myers Squibb Company Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 55. GlaxoSmithKline plc Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 56. Amgen Inc. Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 57. Teva pharmaceutical Industries Ltd. Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 58. Merc & Co. Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 59. AbbVie Inc. Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 60. Takeda Pharmaceutical Co. Ltd. Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 61. Green Cross Corp. Revenue Growth Rate in Fabry Disease Therapeutic Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions